Supplementary Materials

Supplementary Material for:

Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin

Yanqing Liu, Xiaoli Zheng, Qinqin Yu, Hua Wang, Fuqing Tan, Qianying Zhu, Lingmin Yuan, Huidi Jiang, Lushan Yu,* Su Zeng*

*Corresponding author. Email: zengsu{at} (S.Z.); yuls{at} (L.Y.)

Published 20 July 2016, Sci. Transl. Med. 8, 348ra97 (2016)
DOI: 10.1126/scitranslmed.aaf3124

This PDF file includes:

  • Materials and Methods
  • Fig. S1. OCT2 is repressed in RCC.
  • Fig. S2. BSP and MS-AP-qPCR were validated with control DNA template.
  • Fig. S3. DAC treatment demethylates the E-Box at the OCT2 promoter in RCC cell lines.
  • Fig. S4. MLL1 knockdown and DAC treatment do not affect PPIA expression in 786-O cells.
  • Fig. S5. OCT2 contributes to transport and cytotoxicity of oxaliplatin in RCC cells.
  • Fig. S6. Combination with DAC does not sensitize RCC cell lines to cisplatin and carboplatin.
  • Fig. S7. DAC treatment does not restore MATE-2K expression in RCC.
  • Fig. S8. DAC demethylates the E-Box at the OCT2 promoter in xenografts.
  • Fig. S9. DAC induces OCT2 expression in xenografted tumors.
  • Fig. S10. Combination treatment does not increase AOPP serum concentration in Caki-1 xenografts.
  • Fig. S11. Histological analysis was performed on kidney and liver sections collected from Caki-1 xenografts.
  • Fig. S12. Cartoon model illustrates OCT2 transcription machinery in the kidney.
  • Fig. S13. Cartoon model illustrates oxaliplatin transportation in normal renal cells and RCC cells.
  • Table S1. Tissue specimen information.
  • Table S2. TMA information.
  • Table S3. shRNAs used in this study.
  • Table S4. Primers used in this study.
  • Legends for tables S5 and S6

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S5. Methylation analysis results of individual tissues (provided as an Excel file).
  • Table S6. Tumor xenograft data (provided as an Excel file).

[Download Tables S5 and S6]